HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nearly 75% Of US Consumers Use Supplements, Buying More Than 90% In Stores – CRN Survey

Executive Summary

Survey conducted online between in August among nationally representative sample of 3,192 consumers 18 and older, including 2,328 adults who use supplements seasonally, occasionally or regularly.

You may also be interested in...



Gummy Format And Immunity Health Have Legs As Sales Drivers For US Supplement Market

“It's not that gummies have taken over the entire pill format,” says nutritional product business consultant Thomas Aarps. “But the trend is obviously to gummies.” Meanwhile, multiple COVID variants keep consumers attuned to immunity health. “Immunity is big, it's going to be big.”

Dr. Teal’s Tucks In Some Melatonin Topical Sleep Claims After P&G Challenge, Keeps Others Awake

PDC Brands declines to provide support for nine challenged claims for Dr. Teal’s line of balms, lotions, oils, soaps, sprays and other topicals. It continues using those after halting use of 25 other similar claims challenged by P&G, marketer of melatonin-containing ZzzQuil.

NPA Complaint For Preemption Argues New York Swings Wildly With Age-Restricted Sales Law

New York law crosses so many federal regulations it would also affect Rx drug sales while allowing consumers to file complaints alleging businesses violate the law, NPA argues in complaint filed in federal court in New York City.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel